Abbott Is Not Testing Whether TriClip Works. It Is Building the File That Gets It Paid.
Abbott began a 1,000-patient, five-year post-market study of TriClip across 100 sites, generating the durability evidence payers and guidelines require.
The Beats
Analysis
The Briefs
Abbott Is Not Testing Whether TriClip Works. It Is Building the File That Gets It Paid.
A B7-H3 Antibody Drug Conjugate Just Won a Second Phase 3, in a Second Tumour
J&J Won the Ruling on 22 July. Five Days Later It Agreed to Pay $5.5 Billion.
Approval Is Day One. In Canada, Patients Wait Another Five Hundred Days.
Italy Ran an Innovation Test for Eight Years.